Literature DB >> 18941257

Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions.

Lucie Baudino1, Yasuro Shinohara, Falk Nimmerjahn, Jun-ichi Furukawa, Munehiro Nakata, Eduardo Martínez-Soria, Franz Petry, Jeffery V Ravetch, Shin-ichiro Nishimura, Shozo Izui.   

Abstract

Replacement of aspartic acid by alanine at position 265 (D265A) in mouse IgG1 results in a complete loss of interaction between this isotype and low-affinity IgG Fc receptors (Fc gammaRIIB and Fc gammaRIII). However, it has not yet been defined whether the D265A substitution could exhibit similar effects on the interaction with two other Fc gammaR (Fc gammaRI and Fc gammaRIV) and on the activation of complement. To address this question, 34-3C anti-RBC IgG2a and IgG2b switch variants bearing the D265A mutation were generated, and their effector functions and in vivo pathogenicity were compared with those of the respective wild-type Abs. The introduction of the D265A mutation almost completely abolished the binding of 34-3C IgG2a and IgG2b to all four classes of Fc gammaR and the activation of complement. Consequently, these mutants were hardly pathogenic. Although oligosaccharide side chains of these mutants were found to contain higher levels of sialic acids than those of wild-type Abs, the analysis of enzymatically desialylated D265A variants ruled out the possibility that very poor Fc-associated effector functions of the D265A mutants were due to an increased level of the mutant Fc sialylation. Thus, our results demonstrate that aspartic acid at position 265 is a residue critically implicated in triggering the Fc-associated effector functions of IgG, probably by defining a crucial three-dimensional structure of the Fc region.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18941257     DOI: 10.4049/jimmunol.181.9.6664

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

Review 1.  The Role and Function of Fcγ Receptors on Myeloid Cells.

Authors:  Stylianos Bournazos; Taia T Wang; Jeffrey V Ravetch
Journal:  Microbiol Spectr       Date:  2016-12

2.  Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.

Authors:  Eric F Zhu; Shuning A Gai; Cary F Opel; Byron H Kwan; Rishi Surana; Martin C Mihm; Monique J Kauke; Kelly D Moynihan; Alessandro Angelini; Robert T Williams; Matthias T Stephan; Jacob S Kim; Michael B Yaffe; Darrell J Irvine; Louis M Weiner; Glenn Dranoff; K Dane Wittrup
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

3.  The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

Authors:  JianMin Lin; Jared L Spidel; Christopher J Maddage; Katherine A Rybinski; Rina P Kennedy; Candice L M Krauthauser; Young Chul Park; Earl F Albone; Sara Jacob; Matthew T Goserud; Bryon P Martinez; Qimin Chao; Yuhong Zhou; Nicholas C Nicolaides; J Bradford Kline; Luigi Grasso
Journal:  Cancer Biol Ther       Date:  2013-08-28       Impact factor: 4.742

4.  Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways.

Authors:  Polina Weitzenfeld; Stylianos Bournazos; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

5.  Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

Authors:  Alice Tzeng; Byron H Kwan; Cary F Opel; Tejas Navaratna; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

6.  Sialylation determines the nephritogenicity of IgG3 cryoglobulins.

Authors:  Masako Otani; Aki Kuroki; Shuichi Kikuchi; Masao Kihara; Junichiro Nakata; Kiyoaki Ito; Jun-ichi Furukawa; Yasuro Shinohara; Shozo Izui
Journal:  J Am Soc Nephrol       Date:  2012-09-27       Impact factor: 10.121

7.  Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection.

Authors:  S C Kim; W Wakwe; L B Higginbotham; D V Mathews; C P Breeden; A C Stephenson; J Jenkins; E Strobert; K Price; L Price; R Kuhn; H Wang; A Yamniuk; S Suchard; A B Farris; T C Pearson; C P Larsen; M L Ford; A Suri; S Nadler; A B Adams
Journal:  Am J Transplant       Date:  2017-02-25       Impact factor: 8.086

8.  Anti-CD79 antibody induces B cell anergy that protects against autoimmunity.

Authors:  Ian R Hardy; Nadia Anceriz; François Rousseau; Matt B Seefeldt; Eric Hatterer; Magali Irla; Vanessa Buatois; Laurence E Chatel; Andrew Getahun; Ashley Fletcher; Laura Cons; Guillemette Pontini; Nicole A Hertzberg; Giovanni Magistrelli; Pauline Malinge; Mia J Smith; Walter Reith; Marie H Kosco-Vilbois; Walter G Ferlin; John C Cambier
Journal:  J Immunol       Date:  2014-01-17       Impact factor: 5.422

Review 9.  Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.

Authors:  David F Pinelli; Mandy L Ford
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

10.  The Structural Role of Antibody N-Glycosylation in Receptor Interactions.

Authors:  Ganesh P Subedi; Adam W Barb
Journal:  Structure       Date:  2015-07-23       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.